FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Oncology | Biotech Stock | ASCO

ASCO braces for massive data dump before meeting

The analysts devoted to tracking biotech companies in the oncology arena will have their hands full tomorrow night at 9 p.m. EST. That's when ASCO will do an online data dump in advance of its annual meeting, revealing many of the little--and big--details that could spell swift gyrations in the value of a company's shares.

The data blast, which will cover the results from thousands of studies, marks a big change for the cancer group. In the past, ASCO members got an advance look at the data that was being presented, and the numbers oh-so-mysteriously migrated into the hands of investors, who were able to get a jump on the market movers. Last year, for example, you could tell who was going to release positive or negative data by the movement of a company's shares in advance of the meeting.

Analysts say this year's switch will cost them a night's sleep, but look for plenty of headlines over the weekend.

- read the report from the Wall Street Journal

Related Articles:
ASCO plays host to new cancer studies
ASCO spawns wave of new cancer data
Cancer stocks gyrating as ASCO abstracts circulate


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Oncology   Biotech Stock   ASCO